2-(1-氨基乙基)苯甲酸 | 68998-15-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(1-氨基乙基)苯甲酸
• 英文名称: 2-α-aminoethylbenzoic acid
• 英文别名: 2-(1-aminoethyl)-benzoic acid；2-(1-Amino-ethyl)-benzoic acid；2-(1-aminoethyl)benzoic acid
• CAS: 68998-15-2
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: KYZTUNCFUQURFU-UHFFFAOYSA-N

物化性质

• 沸点：
  314.8±25.0 °C(Predicted)
• 密度：
  1.186±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(1-氨基乙基)苯甲酸 在 一水合肼 作用下， 反应 5.0h， 以100%的产率得到4-甲基酞嗪-1(2H)-酮
  参考文献：
  名称：

  Cyclotransformation in the series of fused 5-nitropyridin-2(1H)-ones

  摘要：

  与过量的肼水合物反应的5-硝基吡啶-2(1H)-酮与苯、吡啶和1,2,3-三嗪环的熔合，导致了5-硝基-2-氧基吡啶片段向6-甲基-3-氧基吡唑啉结构的环转化。该环转化具有一般特征；提出了该过程的可能机制。对假定机制的细节在模型化合物上进行了实验确认。

  DOI：

  10.1134/s1070428008020152

文献信息

• [EN] CHELATED PSMA INHIBITORS<br/>[FR] INHIBITEURS CHÉLATÉS DU PSMA
  申请人：CANCER TARGETED TECHNOLOGY LLC

  公开号：WO2012174136A1

  公开（公告）日：2012-12-20

  Compounds as defined herein are provided which are useful in (1) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable diluent; and (3) methods for imaging prostate cancer cells.

  本文定义的化合物可用于：（1）用于检测和/或鉴定表达PSMA的细胞的诊断方法；（2）包含本发明化合物的与药用稀释剂一起的组合物；以及（3）用于成像前列腺癌细胞的方法。
• Amidite for nucleic acid synthesis and nucleic acid synthesizing method
  申请人：Fujihara Tsuyoshi

  公开号：US20080167459A1

  公开（公告）日：2008-07-10

  To provide an amidite for nucleic acid synthesis, which enables a protective group therein to be removed under moderate conditions and can be practically used, and a nucleic acid synthesizing method using the amidite for nucleic acid synthesis. Specifically, the present invention relates to an amidite for nucleic acid synthesis represented by General Formula (I) below, and a nucleic acid synthesizing method using the amidite for nucleic acid synthesis: where X denotes a base; Y denotes a protective group formed of any one of a 4-aminobutyric acid derivative, an o-aminomethylbenzoic acid derivative, an o-aminophenylacetic acid derivative, an o-aminoethylbenzoic acid derivative, an o-aminomethylphenylacetic acid derivative, an o-aminophenylpropionic acid derivative and a 5-aminovaleric acid derivative; and Q denotes one of a hydrogen atom and a hydroxyl group.

  提供一种用于核酸合成的酰胺，其使其中的保护基在温和条件下可以被去除并且可以实际应用，以及使用该核酸合成酰胺的核酸合成方法。具体来说，本发明涉及一种用下面的一般式（I）表示的用于核酸合成的酰胺，以及使用该核酸合成酰胺的核酸合成方法：其中X代表一种碱基；Y代表由4-氨基丁酸衍生物、o-氨基甲基苯甲酸衍生物、o-氨基苯乙酸衍生物、o-氨基乙基苯甲酸衍生物、o-氨基甲基苯乙酸衍生物、o-氨基苯丙酸衍生物和5-氨基戊酸衍生物中的任一形成的保护基；Q代表氢原子或羟基中的一个。
• AMIDITE FOR SYNTHESIZING MODIFIED NUCLEIC ACID AND METHOD FOR SYNTHESIZING MODIFIED NUCLEIC ACID
  申请人：FUJIHARA Tsuyoshi

  公开号：US20090062521A1

  公开（公告）日：2009-03-05

  To provide an excellent amidite for synthesizing modified nucleic acid, which enables a protective group therein to be removed under a moderate condition, thereby stably producing a hydroxyl group-containing modified nucleic acid, and a method for synthesizing modified nucleic acid using the amidite. Specifically, an amidite for synthesizing modified nucleic acid, expressed by General Formula (I): where X represents a base, Y represents a substituent, Z represents a protective group for protecting a hydroxyl group in the substituent, and Q represents one of a hydrogen atom, a hydroxyl group and a hydroxyl group protected by a protective group, wherein the protective group can be removed in an aprotic solvent, and when the protective group is removed, the hydroxyl group emerges in the substituent, and a method for synthesizing modified nucleic acid using the amidite.

  提供一种用于合成修饰核酸的优良酰胺试剂，该试剂可使其中的保护基在适度条件下被去除，从而稳定地产生含有羟基的修饰核酸，并提供一种使用该酰胺试剂合成修饰核酸的方法。具体而言，该酰胺试剂的通式表示为（I）式，其中X代表一种碱基，Y代表一种取代基，Z代表一种用于保护取代基中羟基的保护基，Q代表氢原子、羟基或被保护基保护的羟基中的一种，其中保护基可在无水溶剂中被去除，当保护基被去除时，羟基出现在取代基中，同时提供使用该酰胺试剂合成修饰核酸的方法。
• Therapeutic use of aryl amino acid derivatives
  申请人：——

  公开号：US20040138197A1

  公开（公告）日：2004-07-15

  The compounds of formula (I) are useful in the treatment of faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, neuropathic pain, neuropathological disorders and sleep disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included. 1 wherein R 1 is H, C 1 -C 6 alkyl or C 3 -C 8 cycloalkyl; X is —(CH 2 ) n —C(R 7 )(R 8 )—; Y is a direct link or —(CH 2 ) m —C(R 9 )(R 10 )—; R 7 , R 8 , R 9 and R 10 are independently H or C 1 -C 6 alkyl; or R 8 and R 1 can be taken together with the nitrogen to which R 1 is attached to form a 4-8-membered heterocycloalkyl ring; or R 10 and R 1 can be taken together with the nitrogen to which R 1 is attached to form a 4-8-membered heterocycloalkyl ring; or R 8 and R 10 can be taken together with the carbons to which they are attached to form a 4-8-membered carbocyclic ring; n is 0, 1 or 2; m is 0, 1 or 2; R 2 , R 3 , R 4 and R 5 are independently selected from H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, halogen, hydroxycarbonyl, C 1 -C 6 alkoxycarbonyl, cyano, sulfonyl, C 1 -C 6 alkylsulfonyl, thio, C 1 -C 6 alkylthio, sulfonamide, perfluoro-C 1 -C 6 alkyl, perfluoro-C 1 -C 6 alkoxy, C 3 -C 8 cycloalkyl, 4-8 membered heterocycloalkyl, amino, (C 1 -C 6 alkyl or di-C 1 -C 6 alkyl)amino, aminocarbonyl, (C 1 -C 6 alkyl or di-C 1 -C 6 alkyl)aminocarbonyl, C 1 -C 6 acylamino, (N—C 1 -C 6 alkyl)C 1 -C 6 acylamino, phenyl or monocyclic heteroaryl, wherein phenyl and monocyclic heteroaryl are optionally substituted with C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, halogen, hydroxycarbonyl, C 1 -C 6 alkoxycarbonyl or perfluoro-C 1 -C 6 alkoxy; or any one or two of CR 2 , CR 3 , CR 4 and CR 5 may be replaced with a nitrogen; or R 2 and R 3 or R 3 and R 4 or R 4 and R 5 may be taken together with the carbons to which they are attached to form fused C 5 -C 8 cycloalkyl, 4-8 membered heterocycloalkyl, phenyl or monocyclic heteroaryl; or R 1 and R 2 can be taken together with the nitrogen to which R 1 is attached to form a 4-8-membered heterocycloalkyl ring; or R 8 and R 2 can be taken together with the carbons to which they are attached to form a 4-8-membered carbocyclic or heterocycloalkyl ring; and R 6 is hydroxycarbonyl or a carboxylic acid biostere or a prodrug thereof.

  式(I)的化合物在治疗晕厥发作、运动减退、头颅疾病、神经退行性疾病、抑郁症、焦虑、恐慌、神经病理性疼痛、神经病理性疾病和睡眠障碍方面有用。包括制备最终产品和在过程中有用的中间体的过程。还包括含有一种或多种化合物的制药组合物。其中，R1为H、C1-C6烷基或C3-C8环烷基；X为—(CH2)n—C(R7)(R8)—；Y为直接连接或—(CH2)m—C(R9)(R10)—；R7、R8、R9和R10独立地为H或C1-C6烷基；或R8和R1可以与R1连接的氮一起形成4-8环杂环烷基环；或R10和R1可以与R1连接的氮一起形成4-8环杂环烷基环；或R8和R10可以与它们连接的碳一起形成4-8环碳杂环烷基环；n为0、1或2；m为0、1或2；R2、R3、R4和R5独立地选自H、C1-C6烷基、C1-C6烷氧基、羟基、卤素、羟基羧酸、C1-C6烷氧羰基、氰基、磺酰基、C1-C6烷基磺酰基、硫基、C1-C6烷基硫基、磺酰胺基、全氟C1-C6烷基、全氟C1-C6烷氧基、C3-C8环烷基、4-8环杂环烷基、氨基、(C1-C6烷基或二-C1-C6烷基)氨基、氨基羧酸、(C1-C6烷基或二-C1-C6烷基)氨基羧酸、C1-C6酰胺基、(N-C1-C6烷基)C1-C6酰胺基、苯基或单环杂芳基，其中苯基和单环杂芳基可选择性地被C1-C6烷基、C1-C6烷氧基、羟基、卤素、羟基羧酸、C1-C6烷氧羰基或全氟C1-C6烷氧基取代；或CR2、CR3、CR4和CR5中的任意一个或两个可以被氮取代；或R2和R3或R3和R4或R4和R5可以与它们连接的碳一起形成融合的C5-C8环烷基、4-8环杂环烷基、苯基或单环杂芳基；或R1和R2可以与R1连接的氮一起形成4-8环杂环烷基环；或R8和R2可以与它们连接的碳一起形成4-8环碳杂环烷基环或杂环烷基环；R6为羟基羧酸或羧酸生物立体异构体或其前药。
• POLYMERIC COMPOSITION, POLYMER CAPSULE, AND FABRIC SOFTENER COMPOSITION INCLUDING SAME
  申请人：LG Chem, Ltd.

  公开号：EP3680289A1

  公开（公告）日：2020-07-15

  The present application relates to a polymerizable composition, polymer capsules and a fabric softener composition. The fabric softener composition of the present application comprises polymer capsules in which cationic groups are introduced on the surfaces thereof, so that early release of a fragrance can be suppressed and aromas can be generated depending on rupture of a shell material of the polymer capsules by light friction at certain times. In addition, the polymer capsules of the present application have high adhesion to fibers and are not attached to fibers during washing to minimize the discharged fragrance, so that sufficient aromas can be provided even if a small amount of fragrance is used.

  本申请涉及一种可聚合组合物、聚合物胶囊和织物柔软剂组合物。本申请的织物柔软剂组合物包括聚合物胶囊，在其表面引入阳离子基团，因此可抑制香料的早期释放，并在特定时间通过光摩擦使聚合物胶囊的外壳材料破裂而产生香气。此外，本申请的聚合物胶囊与纤维的粘附力很强，在洗涤过程中不会附着在纤维上，从而最大限度地减少了香味的释放，因此，即使使用少量香料，也能提供足够的香味。